Glioblastoma
Conditions
Interventions
Experimental group:simultaneous integrated boosts radiotherapy PTV1 60Gy/30F
PTV2 66Gy/30F and concurrent adjuvant temozolomide chemotherapy
Control group:Standard radiotherapy PTV 60Gy/30F and concurrent adjuvant temozolomide chemotherapy
Sponsors
Department of Oncology, Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. According to the 2016 WHO classification of central nervous system tumors ,Postoperative patients diagnosed as glioblastoma by histopathology and reported as IDH wild-type by molecular pathology; 2. Aged 18-65 years; 3. Patients who have not been treated with radiotherapy or chemotherapy previously; 4. No history of other malignancies; 5. Liver function: Total bilirubin =80 ml/min; 7. Blood test: Absolute neutrophil count (ANC) >=2x10^9/L, platelet count >=100x10^9/L and hemoglobin >=9g/dL; 8. No serious heart, lung and other important organ dysfunction; 9. KPS score >=80; 10. Signed Informed consent.
Exclusion criteria
Exclusion criteria: 1. Have been treated with anti-tumor therapy, including chemotherapy and radiotherapy; 2. Women in pregnancy or lactation; 3. Patients not cooperating with regular follow-up due to psychological, social, family and geographic reasons; 4. Known to be allergic to chemotherapeutic drugs that may be used; 5. With a severe uncontrolled infection or medical illness; 6. Major organ dysfunction, such as decompensated heart, lung, kidney, liver failure, can not tolerate radiotherapy and chemotherapy; 7. Laboratory examination: Total bilirubin > normal value upper limit (ULN), AST and/or ALT > 1.5 times normal value upper limit (ULN) and accompanied by alkaline phosphatase 2.5 times times normal value upper limit (ULN); 8. Has the fator to influence the medicine, the distribution, the metabolism, the excretion, such as the central nervous system abnormality, the chronic diarrhea, the ascites, the chest water and so on; 9. Long-term use of immunosuppressive agents after organ transplantation; 10. With history of other malignancies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival;objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Countries
China
Contacts
Public ContactJidong Hong
Department of Oncology, Xiangya Hospital, Central South University
Outcome results
None listed